The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure.

ORIGINAL ARTICLE

The size of blood–brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure Hong Chen1 and Elisa E Konofa*gou1,2 Focused ultrasound (FUS) in combination with microbubbles (MBs) has been successfully used in the delivery of various-size therapeutic agents across the blood–brain barrier (BBB). This study revealed that FUS-induced BBB opening size, deﬁned by the size of the largest molecule that can permeate through the BBB, can be controlled by the acoustic pressure as dictated by cavitational mechanisms. Focused ultrasound was applied onto the mouse hippocampus in the presence of systemically administered MBs for trans-BBB delivery of ﬂuorescently labeled dextrans with molecular weights 3 to 2,000 kDa (hydrodynamic diameter: 2.3 to 54.4 nm). The dextran delivery outcomes were evaluated using ex vivo ﬂuorescence imaging. Cavitation detection was employed to monitor the MB cavitation activity associated with the delivery of these agents. It was found that the BBB opening size was smaller than 3 kDa (2.3 nm) at 0.31 MPa, up to 70 kDa (10.2 nm) at 0.51 MPa, and up to 2,000 kDa (54.4 nm) at 0.84 MPa. Relatively smaller opening size (up to 70 kDa) was achieved with stable cavitation only; however, inertial cavitation was associated with relatively larger BBB opening size (above 500 kDa). These ﬁndings indicate that the BBB opening size can be controlled by the acoustic pressure and predicted using cavitation detection. Journal of Cerebral Blood Flow & Metabolism (2014) 34, 1197–1204; doi:10.1038/jcbfm.2014.71; published online 30 April 2014 Keywords: blood–brain barrier; different-size agents; drug delivery; microbubbles; ultrasound

INTRODUCTION Brain diseases or disorders can be difﬁcult to treat through systemic delivery of therapeutic agents, because most agents are blocked by a natural barrier in the brain: the blood–brain barrier (BBB). This barrier is a specialized structure existing between the cerebral vasculature and the brain parenchyma. Different from barriers between peripheral vasculature and other organs in the body, both the transcellular and paracellular pathways are strictly restricted by the BBB because of the paucity of pinocytotic vesicles in cerebral vessels and the presence of tight junctions between adjacent endothelial cells. Certain small lipid-soluble drugs with a molecular weight (MW) o400 Da may cross the BBB.1 Unfortunately, the majority of the therapeutic agents are larger than the size limit, and thus cannot cross the BBB. Focused ultrasound (FUS) in combination with microbubbles (MBs) is an emerging technique that has been successfully used in trans-BBB delivery of therapeutic agents of various sizes, such as chemotherapeutic drugs (MW B500 Da),2 neurotrophins (MWB20 kDa),3 antibodies (MW B150 kDa),4 and gene vectors (MW B4 MDa).5 Although neurosurgical, pharmacologic, or physiologic strategies have been developed to circumvent the BBB for brain drug delivery,1 transcranial FUS in combination with MBs is the only known technique that can induce localized and reversible BBB opening.6,7 Externally generated ultrasound waves can be focused through the intact scalp and skull onto a small focal region (on the order of millimeters) deep into the subcortical structures, which allows highly precise and noninvasive targeting of brain tissues. Microbubbles, which are gas-ﬁlled bubbles coated by protein or lipid shells (diameters of 1 to 10 mm), were originally introduced into the clinic

as blood-pool ultrasound contrast agents, circulating in the vascular space. When encountering an ultrasound beam, they cavitate, which is a broad term for various ultrasound-induced bubble activities, including their volumetric oscillation and collapse. It has been found that MB cavitation in the cerebral vasculature can induce localized BBB opening by stretching the tight junctions and stimulating the formation of vesicles, enabling paracellular and transcellular transports, respectively.7,8 Paracellular transport through intercellular tight junctions is size selective in that only molecules smaller than the gaps between tight junctions can go through; in contrast, transcytotic transport by cellular vesicles carrying the molecules through the endothelial cells is size-independent as vesicles are much larger than most therapeutic agents.9,10 Extensive research has been performed to show the great potential of FUS in the delivery of various-size therapeutic agents; however, studies are limited on the FUS-induced BBB opening size, deﬁned by the size of the largest molecule that can permeate through the BBB. Almost all previous studies used only one speciﬁc-size agent and found the treatment parameters that contributed to the successful delivery of that agent. Only two reported studies have compared the delivery outcomes of different-size agents to assess the maximum BBB opening size. In the ﬁrst study, Choi et al11 used ﬂuorescently labeled dextrans of 3, 70, and 2,000 kDa with respective hydrodynamic diameters of about 2.3, 10.2, and 54.4 nm as model drugs. They found that using 1.525 MHz FUS at 0.57 MPa, 3 and 70 kDa dextrans were delivered trans-BBB, while 2,000 kDa dextran was not, which suggested that there was a size limit associated with FUS-induced BBB opening. In the second study, Marty et al12 used magnetic resonance contrast

1 Department of Biomedical Engineering, Columbia University, New York, New York, USA and 2Department of Radiology, Columbia University, New York, New York, USA. Correspondence: Dr EE Konofa*gou, Department of Biomedical Engineering, Columbia University, 351 Engineering Terrace, Mail Code 8904, 1210 Amsterdam Avenue, New York, NY, USA. E-mail: [emailprotected] This study was supported by NIH grants R01 EB009041 and R01 AG038961 and the Kinetics foundation. Received 20 December 2013; revised 16 March 2014; accepted 21 March 2014; published online 30 April 2014

Focused ultrasound-induced BBB opening size H Chen and EE Konofa*gou

1198 agents of different hydrodynamic diameter (1 to 65 nm) as model drugs and found that the maximum BBB opening size varied between 25 and 65 nm using 1.5 MHz FUS at 0.45 MPa. However, as only a single set of ﬁxed ultrasound parameters was used, the dependence of the BBB opening size on acoustic parameters remained unexplored. Depending on the acoustic pressure, MB cavitation can range from stable cavitation (SC) to inertial cavitation (IC), which are considered to be the main physical mechanisms responsible for FUS-induced BBB opening.13 At low pressure, MBs undergo stable volumetric oscillation, or SC. The oscillating MBs can induce ‘pushing’ and ‘pulling’ forces, as well as shear forces, on the endothelium, which likely increase vascular permeability14 without causing any vascular damage.15 At high pressure, larger MB expansion could induce IC, leading to sudden collapse of the MBs. Microbubbles exert forces on the vessels to a much larger extend and can generate liquid microjets.16 This IC behavior is more forceful and may increase BBB permeability to a larger extent. IC has been shown to be associated with microdamage to the cerebral vessels.15,17 Under the acoustic parameters reported for BBB opening so far, the most dominant damaging effect induced by IC is minor extravasation of blood components such as red blood cells at the sonicated locations.17–21 No ischemic or apoptotic regions were detected that would indicate a compromised blood supply.21 Recent work in nonhuman primates showed that the minimal tissue damage induced after repeated BBB disruption did not cause any detectable behavioral effects.20 The acoustic emissions from SC and IC have been detected by passive cavitation detection (PCD) to monitor MB behavior and improve the safety of BBB opening.17,18,20,22 Until now, PCD has only been used in cavitation detection during FUS-enhanced delivery of magnetic resonance imaging contrast agents (MWo1 kDa)17,18,20,22 and 3 kDa dextran.23 No cavitation detection has been performed to monitor FUS-activated MB behaviors in the delivery of any other larger agents; consequently, the physical mechanisms for how FUS in combination with MBs deliver different-size agents across the BBB have not been fully understood. The main purpose of the present study was thus threefold: (1) to assess the dependence of the BBB opening size on acoustic parameters, speciﬁcally the acoustic pressure; (2) to identify MB cavitation behaviors associated with the trans-BBB delivery of different-size agents; (3) to evaluate the histologic effects associated with the delivery of different-size agents. The BBB opening size was assessed using ﬂuorescently labeled dextrans of 3 to 2,000 kDa. Delivery outcomes of these intravenously administered dextrans after FUS sonication were evaluated based on ﬂuorescence images of brain slices. Passive cavitation detection was performed to monitor MB cavitation behaviors during sonication. Histologic analysis was performed for safety evaluation. For the ﬁrst time, we found the BBB opening size was controllable by the acoustic pressure, and revealed the physical mechanisms associated with the trans-BBB delivery of differentsize agents. The knowledge gained from this study is important toward a better understanding of the mechanisms for FUSinduced BBB opening and provides guidance for developing agent size-speciﬁc FUS treatment protocols.

MATERIALS AND METHODS Preparation of Animals In accordance with the National Institutes of Health Guidelines for animal research, all animal procedures for these experiments were reviewed and approved by the Institutional Animal Care and Use Committee of the Columbia University. This study used four different-size ﬂuorescein-labeled dextrans (3, 70, 500, and 2,000 kDa) to assess their delivery outcomes under three acoustic pressure levels (0.31, 0.51, and 0.84 MPa). Therefore, there were 12 study groups (effective sample size: 4 mice per group) (Table 1). Wild-type adult male mice (strain: C57BL/6, age: 6 to 8 weeks, Journal of Cerebral Blood Flow & Metabolism (2014), 1197 – 1204

masses: 22.5±1.6 g (mean±standard deviation); Harlan Sprague Dawley, Indianapolis, IN, USA) were used. During the whole procedure, the mice were anesthetized with isoﬂurane in oxygen. They were placed prone on a heating pad with a constant temperature output of B401C to maintain their body temperature. Their heads were immobilized by a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). Their head positions were adjusted so that the skin surface at the locations of the bregma and the lambda was evenly leveled by visual inspection, so that the sutures on the heads could later be reliably used for FUS targeting of a brain region. The fur on the head was removed with an electrical trimmer and a depilatory cream. The scalp and skull remained intact.

Focused Ultrasound Experimental Setup A schematic illustration of the main components of the system is shown in Figure 1A. A single-element FUS transducer (center frequency: 1.5 MHz, focal depth: 60 mm, diameter: 60 mm; Imasonic, Besancon, France) was driven by a function generator (33220A; Agilent, Palo Alto, CA, USA) through a nominal 50 dB gain power ampliﬁer (325LA; E&I, Rochester, NY, USA). The transducer was attached to a three-dimensional positioning system (Velmex, Lachine, QC, Canada). A custom-built truncated cone was attached to the transducer and ﬁlled with degassed water to provide acoustic coupling. The cone was immersed in a degassed-water container. The bottom of the water container had a window sealed with an almost acoustically and optically transparent membrane. The container was placed on the mouse head and coupled with degassed ultrasound gel. Acoustic emissions arising from MB cavitation were acquired by a passive cavitation detector (center frequency 10 MHz; focal length 60 mm; Olympus NDT, Waltham, MA, USA). It was positioned through a central hole of the FUS transducer and confocally aligned with the FUS transducer. The signals received by the detector were ampliﬁed by 20 dB (Model 5800; Panametrics-NDT, Waltham, MA, USA) and then digitized (Razor Express CompuScope 1422; Gage Applied Technologies, Inc., Lachine, QC, Canada) at a sampling frequency of 50 MHz. A custom Matlab program (Mathworks Inc., Sherborn, MA, USA) was used to acquire the acoustic emission signals during the exposure of each ultrasound pulse. The FUS transducer was characterized as described elsewhere.24 The pressures reported here were all peak-negative pressures derated by 18% of that measured in water to account for skull attenuation.24 The dimensions of the beam in water had a lateral and axial full-width at half-maximum pressure of 1.3 and 13.0 mm, respectively.

Focused Ultrasound Sonication Commercially available Deﬁnity MBs (mean diameter range: 1.1 to 3.3 mm, Lantheus Medical Imaging, North Billerica, MA, USA) were used in this study. Those are octaﬂuoropropane gas bubbles coated by a lipid shell. After activation following the manufacturer’s instructions, MBs were injected into each mouse through the tail vein at a dose of 0.05 mL/g of body weight. This dose was comparable to the clinical dose (0.01 mL/g) allowed by the FDA (Food and Drug Administration) for diagnostic purposes in humans. Fluorescein-tagged dextrans (Invitrogen, Carlsbad, CA, USA) of four sets of distinct MWs were used as model drugs: 3 kDa (D3306, hydrodynamic diameter DH B2.3 nm), 70 kDa (D1822, DH B10.2 nm), 500 kDa (D7136, DH B30.6 nm), and 2,000 kDa (D7137, DH B54.4 nm).11,25 For each study, 2 mg of one speciﬁc-MW dextran was dissolved in 100 mL saline and injected to one mouse. Dextrans were chosen as model therapeutic compounds because they are known to be biologically and chemically inert and available in various MWs. These four dextrans were used to represent the broad MW range of the therapeutic agents that have been successfully delivered across the BBB. Fluorescein-labeled dextrans were selected because they have the widest range of MWs among all the commercially available ﬂuorescently labeled dextrans. The left hippocampus of each mouse was selected as the targeted region of interest and the right hippocampus was used as a control. Each animal served as its own control, thereby reducing the variability caused by physiologic differences among animals. Before sonication, a grid system to locate the sutures of the skull was used for the targeting procedure (see ref. 24 for more details). Brieﬂy, to target the left hippocampus, the FUS transducer was laterally moved 3 mm to the left of the sagittal suture and 2 mm anterior of the lambdoid suture. The focal point of the FUS was placed 3 mm beneath the skull, which was at about the center of the hippocampus. Ultrasound sonication with a pulse rate of 5 Hz and a pulse duration of 1.3 ms (2,000 cycles) was applied to the left hippocampus with a peaknegative pressure of 0.31, 0.51, or 0.84 MPa. About 6 seconds after sonication started, MBs mixed with one of the four dextrans were injected & 2014 ISCBFM

Focused ultrasound-induced BBB opening size H Chen and EE Konofa*gou

1199

So n

in g im ag d an

Water cone

Se ct io n

FUS (1.5 MHz)

ic M atio Bs n +d st ex ar t tra So n ni in ca je ct tio io n n e nd Pe rfu si on fix at io n

PCD (10 MHz)

Water container Ultrasound gel

0 6s

11 min 20 min

4 days

Mouse

Figure 1. (A) Schematic illustration of the experimental setup. A 1.5-MHz single element focused ultrasound (FUS) transducer was used for blood–brain barrier opening. It was confocally aligned with a transducer for passive cavitation detection (PCD). The left hippocampus of each mouse was targeted during sonication and the right hippocampus was used as the control. (B) Illustration of the experimental timeline. Sonication started B6 seconds before the injection of a mixture of Definity microbubbles and one dextran with a molecular weight of 3, 70, 500 or 2,000 kDa. During the 11-minute sonication, cavitation detection was performed. The mice were transcardially perfused and fixed at B20 minutes after dextran injection and then the brain tissue was sectioned for fluorescence imaging. into the tail vein of each mouse (see the experiment timeline in Figure 1B). The cavitation emission signals acquired within that 6 seconds provided baselines for cavitation quantiﬁcation. The total sonication time was 11 minutes.

Blood–Brain Barrier Opening Quantiﬁcation At 20-minute after the dextran injection (Figure 1B), the mice were transcardially perfused with 30 mL of phosphate-buffered saline and 60 mL of 4% paraformaldehyde. The brains were extracted from the skull on the next day and postﬁxed in paraformaldehyde overnight, followed by cryoprotection for another 24 hours. The brains were then sequentially sectioned using a cryostat into 60-mm-thick slides in the horizontal orientation. Sections were imaged using a microscope (BX61; Olympus, Melville, NY, USA) equipped with a ﬂuorescein ﬁlter set (excitation ﬁlter: 467 to 498 nm; emission ﬁlter: 513 to 556 nm) and an Olympus DP30BW digital camera. Five sequential sections with two dorsal sections, two ventral sections, and a reference midline section, which were determined by anatomical landmarks, were selected for analysis using a custom Matlab (Mathworks Inc., Natick, MA, USA) program as follows. The left (sonicated) and right (nonsonicated) hippocampi on each section were manually outlined. A circle with a diameter of 200 pixels was selected outside the hippocampi, and three times of the standard deviation above the mean pixel intensity within the circle was used to represent the background autoﬂuorescence intensity. To compare among animals, all the ﬂuorescence images were normalized by dividing their corresponding background ﬂuorescence intensities. Fluorescence pixels due to dextran delivery were separated from background autoﬂuorescence by identifying pixels with intensities above the background autoﬂuorescence intensity in both hippocampi. On each section, we then calculated the ﬂuorescence enhancement by subtracting the total intensities of the identiﬁed pixels on the left from that on the right. We also calculated the percent of ﬂuorescently enhanced pixel numbers by subtracting the total number of identiﬁed pixels on the right from that on the left and then dividing the total number of pixels in the left hippocampus. Finally, two parameters were used to quantify the trans-BBB delivery outcomes for each brain. (1) Average ﬂuorescence intensity was deﬁned to represent the relative amounts of dextrans delivered to the targeted hippocampus. It was calculated by the mean of the ﬂuorescence enhancement across the ﬁve sequential sections. (2) Average area of ﬂuorescence was deﬁned to estimate the spatial distributions of the delivered dextrans, which represented how diffuse the dextrans were. It was calculated by the mean of the percent ﬂuorescently enhanced pixel numbers for the ﬁve selected sections. Special care was taken so that brains with perfusion or sectioning artifacts were not included for the analysis.

Microbubble Cavitation Emission Quantiﬁcation The acoustic emissions from the ultrasound-activated MBs were detected and quantiﬁed using stable cavitation dose (SCD) and inertial cavitation dose (ICD) to assess the ‘amount’ of energy associated with the two types of cavitation activities: SC and IC, respectively. They were calculated on the basis of the frequency content of the acoustic emission: SCD was derived from the harmonic emissions while ICD was from the broadband emissions.23,26 Mice with abnormal cavitation signals were not included & 2014 ISCBFM

(for example, cases showing high superharmonics before the injection of MBs, caused by air bubbles trapped on the skin or in the ultrasound gel). A fast Fourier transform was performed for each signal acquired during the sonication of each ultrasound pulse. Frequency spectra between the th 4 and 10th harmonics were used for SC and IC quantiﬁcation to eliminate any contributions from the FUS beam. The harmonic (nf, n ¼ 4, 5, ..., 10) and ultraharmonic (nf/2, n ¼ 9, 11, y 21) frequencies were ﬁltered out by excluding ±150 kHz bandwidths around each of them.18 This bandwidth was designed to be ﬁltered to ensure that SC response was not included in the IC calculation. The root mean square of the ﬁltered spectrum was calculated to represent the IC level for each pulse. Meanwhile, the harmonic levels were obtained by ﬁrst calculating the root mean square of the maximum amplitudes within the ±150 kHz bandwidths of all harmonics, and then subtracting the corresponding IC level so that the IC activity was not included in the SC quantiﬁcation. Levels of IC and SC were calculated for all the pulses acquired during the 11minute sonication. To minimize variation caused by differences among animals, signals acquired within the initial 6 seconds before the injection of MBs were used to quantify the background cavitation activities. The background SC level was deﬁned by three standard deviations above the mean of the background SC level. Stable cavitation dose was calculated by integrating the SC level above the background through the entire exposure ‘on’ time (‘on’ time ¼ pulse length total number of pulses). The ICD was similarly calculated using the IC levels of the signals acquired before and after the injection of MBs.

Histologic Analysis Whole brain histologic examinations were performed using hematoxylin and eosin (H&E) staining for general histology. Following the same treatment protocol described before, six additional mice after sonication at 0.51 MPa (n ¼ 3) and 0.84 MPa (n ¼ 3) were perfused and ﬁxed in 4% paraformaldehyde. After postﬁxation processing, the brains were parafﬁn embedded and then sectioned horizontally at 6 mm thickness in 10 separate levels with 180 mm intervals. At each level, four sections were acquired and stained with H&E. Bright-ﬁeld images of the stained sections were acquired using the same microscope (BX61; Olympus) as that used for ﬂuorescence imaging but with an Olympus DP25 camera. Histologic evaluation was performed by a trained observer without knowledge of the location and parameters of sonication. Both the sonicated and nonsonicated hippocampi were evaluated.

Statistical Analysis Statistical analysis was performed using GraphPad Prism (Version 5.01, La Jolla, CA, USA). For each study group (Table 1), the mean±standard deviation of the average ﬂuorescence intensity and area of ﬂuorescence for each group were calculated. Successful dextran delivery was concluded if both the average ﬂuorescence intensity and the area of ﬂuorescence were statistically signiﬁcantly higher than zero (one-tailed, one-sample Student’s t-tests). Unpaired two-tailed Student’s t-tests were used to determine whether the ICD and the SCD were signiﬁcantly different between any two groups. A P value of o0.05 was considered to represent a signiﬁcant difference in all the analyses. Journal of Cerebral Blood Flow & Metabolism (2014), 1197 – 1204

Focused ultrasound-induced BBB opening size H Chen and EE Konofa*gou

1200 RESULTS Focused Ultrasound-Induced Blood–Brain Barrier Opening Figure 2 shows representative ﬂuorescence images obtained from mice administered with the four dextrans and sonicated at their left hippocampi at a pressure of 0.84 MPa. Images on the left exhibited the successful delivery of the four dextrans in the FUS-targeted hippocampi; images on the right display the corresponding nonsonicated, contralateral hippocampi. Each pair of images was obtained from a mouse with the highest average ﬂuorescence intensity, as well as the highest percent area of ﬂuorescence, of one speciﬁc-size dextran. The control hippocampi showed no or minimal dextran accumulation. In contrast, FUS-treated hippocampi showed enhancement of all the four agents, but with distinct characteristics. A single sonication resulted in an almost hom*ogeneous distribution of 3 kDa dextran throughout the left hippocampus (Figure 2A). When the dextran size increased to 70 kDa (Figure 2C), ﬂuorescence was less hom*ogenously distributed compared with that of the 3-kDa dextran case. The 500-kDa dextran case (Figure 2E) showed signiﬁcantly lower total ﬂuorescence with less diffusion in the left hippocampus compared with the other two smaller-size dextrans. In the hippocampus injected with 2,000 kDa dextran (Figure 2G), the level of ﬂuorescence was the lowest among the four dextrans and the spatial distribution of ﬂuorescence was characterized by isolated spots. Quantitative assessment indicated that the average ﬂuorescence intensities for the four cases were 1.47 106, 0.44 106, 0.17 106, and 0.07 106, respectively; and the average percent areas of ﬂuorescence were 90.11%, 28.20%, 11.27%, and 2.76%, respectively. In summary, it was shown that as the dextran MW increased, not only did the ﬂuorescence intensity decrease but also its distribution became increasingly heterogeneous in the targeted hippocampi. Figure 3 provides a summary of the quantiﬁcation results for the delivery outcomes of the four dextrans at different pressures. Detailed statistical information of the BBB opening outcomes is summarized in Table 1. At 0.31 MPa, none of the four tested dextrans was signiﬁcantly delivered across the BBB after FUS sonication. At 0.51 MPa, only relatively smaller-size dextrans (3 and 70 kDa) were successfully delivered but not the relative larger-size dextrans (500 and 2,000 kDa). All dextrans were delivered across the BBB when the pressure increased to 0.84 MPa. This is indicative that the BBB opening size was smaller than 3 kDa (DH B2.3 nm) at 0.31 MPa, up to 70 kDa (DHB10.2 nm) at 0.51 MPa, and up to 2,000 kDa (DH B54.4 nm) at 0.84 MPa. Figure 3 also shows that as the dextran MW increased, the ﬂuorescence intensity and area of ﬂuorescence decreased at 0.84 MPa, which was consistent with the previous observation based on Figure 2. The mean ﬂuorescence intensity in the case of 3 kDa dextran at 0.84 MPa was 4.21, 11.09, and 24.40 folds of that in the cases of the 70, 500, and 2,000 kDa dextrans, respectively (Table 1). The mean area of ﬂuorescence for the four dextrans (3, 70, 500, and 2,000 kDa) at 0.84 MPa was 82.66%, 25.55%, 8.53%, and 2.23%, respectively (Table 1). It should be pointed out that although larger-size dextrans were successfully delivered across the BBB at 0.84 MPa, the ﬂuorescence intensity and area of ﬂuorescence decreased dramatically as the dextran size increased. Microbubble Cavitation Emissions Figure 4 summarizes ICDs and SCDs at the three pressure levels for the four different-size dextrans. Microbubble cavitation was independent of the dextran MWs, as no statistically signiﬁcant difference was found in ICD or SCD among the four dextrans. Therefore, results obtained for different-size dextrans at the same pressure were plotted together. The mean SCD shows a trend of increase with pressure; however, no signiﬁcant difference among Journal of Cerebral Blood Flow & Metabolism (2014), 1197 – 1204

3 kDa

70 kDa

500 kDa

2000 kDa

Figure 2. Horizontal sections of the left (sonicated) and right (nonsonicated) hippocampal regions of four mouse brains injected with different-size dextrans: (A, B) 3 kDa, (C, D) 70 kDa, (E, F) 500 kDa, and (G, H) 2,000 kDa. The dash lines highlight the boundaries of the hippocampal regions. The ultrasound pressure was 0.84 MPa for the four cases. These images show that higher amounts and larger areas of dextran delivery were achieved for smaller-size dextrans. The scale bar represents 1 mm.

the different groups was found (Figure 4A). The ICD at 0.84 MPa was statistically higher than those at 0.51 and 0.31 MPa (Figure 4B), indicating that the threshold for IC was between 0.51 and 0.84 MPa. & 2014 ISCBFM

Focused ultrasound-induced BBB opening size H Chen and EE Konofa*gou

1201

Fluorescence intensity

2.0

Histologic Effects Histologic analysis was performed on additional mouse brains sonicated at 0.51 or 0.84 MPa, which were the pressure thresholds for signiﬁcant increases in the delivery of relative smaller-size dextrans (3 and 70 kDa) and larger-size dextrans (500 and 2,000 kDa), respectively. At 0.51 MPa, which is below the IC threshold, no tissue damaging effects, such as dead neurons, necrotic sites, or hemorrhage, were detected in the FUS-sonicated hippocampi (Figure 5A), as well as the nonsonicated hippocampi (Figure 5B), in all the three mouse brains. At 0.84 MPa, which is above the IC threshold, two out of the three mouse brains sonicated at 0.84 MPa showed minimal microscopic damage. Microscopic images from the one with more obvious damage are shown in Figures 5C and D. A few extravasated red blood cells and a small area of microvacuolations were found only within the FUS-sonicated hippocampus (Figure 5C), while the nonsonicated hippocampus remained intact (Figure 5D). In summary, no microscopic damage was associated with the delivery of relative smaller-size dextrans (3 and 70 kDa), while minimal microscopic tissue damage could be associated with the delivery of relative larger-size dextrans (500 and 2,000 kDa). A summary of our ﬁndings is as follows. (1) The pressure threshold for a statistically signiﬁcant increase in the delivery of 3 and 70 kDa dextrans was 0.51 MPa. Meanwhile, a signiﬁcant increase in ICD was observed only at 0.84 MPa. These results indicated that signiﬁcant enhancement in the delivery of 3 and 70 kDa dextrans can occur with SC only, without any microscopic tissue damage. (2) The threshold for a signiﬁcant increase in the delivery of 500 and 2,000 kDa dextrans was 0.84 MPa, which was also the pressure at which signiﬁcant IC was observed with no difference in SC. This suggested that IC was the main mechanism for the delivery of 500 and 2,000 kDa dextrans. Minimal microscopic damage can be associated with their delivery. These two ﬁndings together indicated: (1) trans-BBB delivery of different-size agents through FUS-induced BBB opening depended on the acoustic pressure; and (2) the BBB opening size was dictated by cavitational mechanisms.

106 3 kDa 70 kDa 500 kDa 2000 kDa

1.5

1.0

0.5

* 0 0.31

0.51 Pressure (MPa)

0.84

Area of fluorescence (%)

100 *

3 kDa 70 kDa 500 kDa 2000 kDa 50

* *

0 0.31

0.51 Pressure (MPa)

0.84

Figure 3. (A) Average fluorescence intensity and (B) average area of fluorescence for the 3, 70, 500, and 2,000 kDa dextrans sonicated at 0.31, 0.51, and 0.84 MPa. The pressure threshold for significant increases in both fluorescence and area of fluorescence was 0.51 MPa for 3 and 70 kDa dextrans. But it increased to 0.84 MPa for the 500 and 2,000 kDa dextrans. Stars indicate groups with fluorescence intensity or area of fluorescence statistically significant higher than zero (Po0.05).

Table 1. Group

1 2 3 4 5 6 7 8 9 10 11 12

DISCUSSION Despite a rapidly growing number of studies in FUS-induced BBB opening, studies on the BBB opening size are limited. For the ﬁrst time, we showed that the FUS-induced BBB opening size depended on the acoustic pressure; and revealed that the cavitational mechanisms were different for the signiﬁcant delivery of different-size agents.

Summary of the BBB opening quantification results # Of mice

Dextran MW (kDa)

Pressure (MPa)

Fluorescence intensity mean±s.d. ( 106)

P value (fluorescence intensity40)

Area of fluorescence mean±s.d. (%)

P value (area of fluorescence40)

4 4 4 4 4 4 4 4 4 4 4 4

3 70 500 2,000 3 70 500 2,000 3 70 500 2,000

0.31 0.31 0.31 0.31 0.51 0.51 0.51 0.51 0.84 0.84 0.84 0.84

0.01±0.02 0.06±0.06 0.01±0.01 0.01±0.01 0.31±0.06 0.28±0.12 0.03±0.04 0.02±0.03 1.22±0.27 0.29±0.16 0.11±0.05 0.05±0.02

0.20 0.08 0.08 0.93 0.00 0.01 0.11 0.10 0.00 0.02 0.01 0.01

0.75±1.53 4.57±4.75 0.64±1.17 0.39±0.31 29.93±5.00 17.15±5.79 2.17±2.70 1.28±1.51 82.66±9.55 25.55±12.65 8.53±2.09 2.23±0.37

0.20 0.08 0.18 0.95 0.00 0.01 0.10 0.09 0.00 0.01 0.00 0.00

Successful delivery? No No No No Yes Yes No No Yes Yes Yes Yes

BBB, blood–brain barrier; MW, molecular weight.

& 2014 ISCBFM

Journal of Cerebral Blood Flow & Metabolism (2014), 1197 – 1204

Focused ultrasound-induced BBB opening size H Chen and EE Konofa*gou

1202 p0.05

p>0.05

Inertial cavitation dose (V·s)

Stable cavitation dose (V·s)

p>0.05

4 3 2 1 0 0.31

0.51 Pressure (MPa)

0.4 0.3 0.2 0.1 0.0

0.84

3 kDa

70 kDa

The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. - PDF Download Free (2024)

References